"Santa Maria della Speranza" Hospital
- Address
- lock Available on a paid plan
Santa Maria della Speranza Hospital - Respiratory Medicine Research Center
Santa Maria della Speranza Hospital operates a specialized respiratory research center with particular expertise in asthma management and therapeutic interventions. The facility focuses on advancing treatment options for patients with moderate to severe asthma, aligning with international guidelines such as GINA Step 4 and Step 5 classifications.
- Comparative safety studies of inhaled asthma medications and delivery systems
- Evaluation of novel propellant formulations in pressurized metered-dose inhalers (pMDI)
- Bronchoconstriction assessment and respiratory safety monitoring
The center demonstrates significant capability in conducting double-blind, active-controlled trials for respiratory therapeutics, with specialized infrastructure for evaluating inhaler formulation technologies and their clinical impact. Their research contributes to the development of more environmentally sustainable and clinically effective asthma treatment delivery systems, particularly in assessing the safety profiles of different propellant agents in combination therapies for controlled moderate to severe asthma.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in "Santa Maria della Speranza" Hospital
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE | F. Hoffmann-La Roche AG | Phase III | Not Recruiting | Jul 2023 | Jul 2025 |
IMP list
lock Showing 1 of 5 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Astegolimab | 1 | Unknown | 2023-07-14 | 2023-07-14 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.